Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D06XES
|
|||
Drug Name |
Melphalan
|
|||
Synonyms |
melphalan; 148-82-3; Alkeran; Melfalan; L-PAM; Phenylalanine mustard; L-Sarcolysine; L-Sarcolysin; L-Phenylalanine mustard; p-L-Sarcolysin; Levofalan; Melphalanum; Levopholan; Melfalano; Levofolan; L-Sarkolysin; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; Phenylalanine nitrogen mustard; p-Di-(2-chloroethyl)amino-L-phenylalanine; p-Bis(beta-chloroethyl)aminophenylalanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; Melphalanum [INN-Latin]; p-N-Bis(2-chloroethyl)amino-L-phenylalanine; Melfalano [INN-Spanish]; 4-(Bis(2-chloroet; Melphalan
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Approved | [1] | |
Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [2] | ||
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL |
|||
Formula |
C13H18Cl2N2O2
|
|||
Canonical SMILES |
C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl
|
|||
InChI |
1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1
|
|||
InChIKey |
SGDBTWWWUNNDEQ-LBPRGKRZSA-N
|
|||
CAS Number |
CAS 148-82-3
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:28876
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Abundace of Studied Microbe(s) Regulated by Drug | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
Studied Microbe: Parabacteroides
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Increase | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Parabacteroides was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Bifidobacterium was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
Studied Microbe: Atopobium
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Increase | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Atopobium was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
Studied Microbe: Collinsella
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Collinsella was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
Studied Microbe: Adlercreutzia
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Adlercreutzia was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
Studied Microbe: Citrobacter
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Increase | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Citrobacter was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
Studied Microbe: Klebsiella
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Increase | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Klebsiella was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
Studied Microbe: Blautia
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Blautia was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
Studied Microbe: Clostridium
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Clostridium was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
Studied Microbe: Coprococcus
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Coprococcus was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
Studied Microbe: Dorea
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Dorea was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
Studied Microbe: Lachnospira
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Lachnospira was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
Studied Microbe: Oscillospira
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Oscillospira was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
Studied Microbe: Roseburia
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Roseburia was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
Studied Microbe: Ruminococcus
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Ruminococcus was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Increase | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Enterococcus was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Tissierellales | ||||
Studied Microbe: Anaerococcus
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Anaerococcus was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
Studied Microbe: Megasphaera
Show/Hide Hierarchy
|
[3], [4] | |||
Hierarchy | ||||
Abundance Change | Increase | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Non-Hodgkin's lymphoma | |||
Description | The abundance of Megasphaera was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). |
References | Top | |||
---|---|---|---|---|
REF 1 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 201379. | |||
REF 2 | ClinicalTrials.gov (NCT04380376) Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia. U.S. National Institutes of Health. | |||
REF 3 | Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther. 2015 Sep;42(5):515-28. | |||
REF 4 | Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome. 2018 May 22;6(1):92. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.